Story perspectives

FDA Guides Oncology Radiopharmaceuticals: Non-Invasive Treatments on the Rise

8/20/2025

23 3

Summary

Story summary

The FDA issued draft guidance for optimizing dosages in radiopharmaceutical therapies (RPTs) for oncology, stressing trial design and safety.
Mike Ritchie from Champions Oncology emphasized the significance of tumor sensitivity to radio ligands in radiopharmaceutical advancements.
Paul Hendrix chose stereotactic body radiation therapy (SBRT) over surgery for early-stage lung cancer, reflecting a trend towards non-invasive treatments.
Dr. Drew Moghanaki leads a national trial comparing SBRT and surgery, reporting no early survival differences so far.

1 of 1

Story summary

The FDA issued draft guidance for optimizing dosages in radiopharmaceutical therapies (RPTs) for oncology, stressing trial design and safety.
Mike Ritchie from Champions Oncology emphasized the significance of tumor sensitivity to radio ligands in radiopharmaceutical advancements.
Paul Hendrix chose stereotactic body radiation therapy (SBRT) over surgery for early-stage lung cancer, reflecting a trend towards non-invasive treatments.
Dr. Drew Moghanaki leads a national trial comparing SBRT and surgery, reporting no early survival differences so far.